ArticleJournal of gastrointestinal oncology2023

A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer.

Shigeo Higami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.